Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INO 
Inovio Pharmaceuticals Inc (INO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/04/2025: INO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.77% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.43M USD | Price to earnings Ratio - | 1Y Target Price 7.83 |
Price to earnings Ratio - | 1Y Target Price 7.83 | ||
Volume (30-day avg) 1065635 | Beta 0.92 | 52 Weeks Range 1.68 - 14.75 | Updated Date 03/30/2025 |
52 Weeks Range 1.68 - 14.75 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-04 | When After Market | Estimate -0.832 | Actual -0.6 |
Profitability
Profit Margin - | Operating Margin (TTM) -17410.77% |
Management Effectiveness
Return on Assets (TTM) -49.45% | Return on Equity (TTM) -115.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -18814050 | Price to Sales(TTM) 291.31 |
Enterprise Value -18814050 | Price to Sales(TTM) 291.31 | ||
Enterprise Value to Revenue 128.41 | Enterprise Value to EBITDA -1.09 | Shares Outstanding 36667200 | Shares Floating 33103900 |
Shares Outstanding 36667200 | Shares Floating 33103900 | ||
Percent Insiders 0.68 | Percent Institutions 36.6 |
Analyst Ratings
Rating 3.83 | Target Price 10.67 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Inovio Pharmaceuticals Inc
Company Overview
History and Background
Inovio Pharmaceuticals Inc. was founded in 1979, initially focused on electroporation drug delivery. The company pivoted towards DNA medicines and vaccines, developing a platform technology for treating and preventing various diseases.
Core Business Areas
- DNA Medicines: Develops and commercializes DNA medicines for infectious diseases, cancer, and other diseases.
Leadership and Structure
Joseph Kim is the CEO. The company operates with a functional organizational structure, with departments focused on R&D, clinical development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- VGX-3100 (Cervical Dysplasia): An investigational DNA medicine for the treatment of high-grade cervical dysplasia caused by HPV-16 and HPV-18. Currently awaiting trial results. Competitors include companies developing alternative treatments for HPV-related diseases, such as surgical procedures and other therapeutic interventions.
- INO-4800 (COVID-19 Vaccine): An investigational DNA vaccine for COVID-19. Development was discontinued. Competitors were mRNA vaccines like Pfizer (PFE) and Moderna (MRNA), and Johnson & Johnson (JNJ) viral vector vaccine.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with significant regulatory hurdles. The market for vaccines and therapeutics is substantial and growing.
Positioning
Inovio is positioned as a biotechnology company specializing in DNA medicines. It aims to develop novel therapies and vaccines through its proprietary platform technology.
Total Addressable Market (TAM)
The TAM for vaccines and therapeutics is substantial, estimated in the hundreds of billions of dollars. Inovio aims to capture a share of this market through its DNA medicine platform but has struggled to gain traction compared to larger players.
Upturn SWOT Analysis
Strengths
- Proprietary DNA medicine platform
- Extensive clinical trial pipeline
- Intellectual property portfolio
Weaknesses
- Limited commercialized products
- Dependence on funding and partnerships
- Past clinical trial setbacks
Opportunities
- Partnerships and collaborations
- Expansion of clinical trial programs
- Potential for breakthrough DNA medicines
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- JNJ
Competitive Landscape
Inovio faces stiff competition from established pharmaceutical companies with greater resources and more advanced clinical programs. Inovio's advantage lies in its DNA medicine platform, but it needs to demonstrate clinical success to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Inovio's historical growth has been driven by its R&D efforts and clinical trial advancements.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include focusing on advancing its DNA medicine pipeline and seeking partnerships for clinical development.
Summary
Inovio Pharmaceuticals is a biotechnology company focused on DNA medicines. It has a novel platform but faces significant competition and has yet to achieve commercial success. Its future depends on successful clinical trials and strategic partnerships. Investors should be aware of the inherent risks in biotech investing.
Similar Companies
- MRNA
- VXRT
- BNTX
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and should not be considered financial advice. Investment decisions should be based on individual circumstances and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inovio Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Plymouth Meeting, PA, United States | ||
IPO Launch date 1998-02-12 | CEO, President & Director Dr. Jacqueline E. Shea Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | Website https://www.inovio.com |
Full time employees 134 | Website https://www.inovio.com | ||
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.